909849-04-3

Basic information

• Product Name: 5-bromo-2-[4-(trifluoromethoxy)phenyl]pyrimidine
• Synonyms: 5-bromo-2-[4-(trifluoromethoxy)phenyl]pyrimidine
• CAS NO: 909849-04-3
• Molecular Weight: 319.081
• Mol File: 909849-04-3.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: 5-bromo-2-[4-(trifluoromethoxy)phenyl]pyrimidine(CAS DataBase Reference)
• NIST Chemistry Reference: 5-bromo-2-[4-(trifluoromethoxy)phenyl]pyrimidine(909849-04-3)
• EPA Substance Registry System: 5-bromo-2-[4-(trifluoromethoxy)phenyl]pyrimidine(909849-04-3)

Safety Data

• Hazardous Substances Data: 909849-04-3(Hazardous Substances Data)

Upstream product

• 183438-24-6 5-bromo-2-iodopyrimidine 
• 139301-27-2 4-trifluoromethoxyphenylboronic acid 

Downstream Products

• 1263417-28-2 C₁₃H₁₁F₃N₂O₄S 
• 1257426-66-6 5-(bromomethyl)-2-[4-(trifluoromethoxy)phenyl]pyrimidine 
• 1257426-65-5 {2-[4-(trifluoromethoxy)phenyl]-5-pyrimidinyl}methanol 
• 1257426-50-8 (6S)-2-nitro-6-({2-[4-(trifluoromethoxy)phenyl]-5-pyrimidinyl}methoxy)-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazine 
• 1257426-64-4 2-[4-(trifluoromethoxy)phenyl]-5-pyrimidinecarbaldehyde 

Relevant articles and documents

Pyrazolo[1, 5-a]pyridine compound and use thereof

The invention discloses a pyrazolo[1, 5-a]pyridine compound with the structure characteristic shown in the formula (I) or its pharmaceutically acceptable salt, stereoisomer or prodrug molecule and a use thereof. The compound has good in-vitro anti-tubercle bacillus activity, has the minimal inhibitory concentration (MIC) less than 0.1 micrograms per milliliter and partial MIC of 0.01 micrograms per milliliter and has strong inhibition effects on a clinically sorted multi-drug-resistant tuberculosis (MDR-TB) strain. In an in-vivo experiment, at a dosage of 20mg/kg/d, the pyrazolo[1, 5-a]pyridine compound can effectively eliminate H37Ra infection in a mouse and is a novel anti-tuberculosis compound.

NITROIMIDAZOOXAZINES AND THEIR USES IN ANTI-TUBERCULAR THERAPY

The present invention relates to novel nitroimidazooxazines, to their preparation, and to their use as drugs for treating Mycobacterium tuberculosis and other microbial infections, either alone or in combination with other anti-infective treatments.